Fortrea price to free cash flow FTRE

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Oct 23, 2026: 11.5×
2-year median: 8.1×
Against its 2-year history: 86th; percentile: 0 is its lowest day, 100 its highest
2-year range: 2.0× to 21.6×
Peer median: 27.2×

Fortrea's price to free cash flow is 11.5× as of Oct 23, 2026.

That is above its 2-year median of 8.1×, higher than on 86% of days in the last 2 years.

Over that time it ranged from 2.0× in Apr 2025 to 21.6× in Jul 2024.

The median for 9 diagnostics and research stocks of a similar size is 27.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	11.5×	6.6×	12.9×
2025	3.4×	2.0×	7.7×
2024	7.7×	6.5×	21.6×

Against its peers

Companies in Medical - Diagnostics & Research nearest Fortrea's size, closest first, today.

Company	Price to free cash flow
FTREFortrea	11.5×
CDNACareDx	n/m
VCYTVeracyte	23.2×
BLLNBillionToOne	153×
LNTHLantheus	16.8×
CAICaris Life Sciences	73.0×
BIOBio-Rad Laboratories	28.0×
NRCNRC Health	22.4×
RVTYRevvity	31.7×
MEDPMedpace	26.4×
Peer median	27.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Fortrea

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.